The patient must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1).
Patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
No metastatic disease on cross-sectional imaging (according to Response Evaluation Criteria in Solid Tumors [RECIST] version [v]1.1 criteria)
Patients must have radiographically measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria
Measurable disease (at least one target lesion) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1);
Measurable disease by CT or MRI per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) criteria
Have measurable disease according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).
For all dose expansion arms, participants must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Presence of measurable lesions by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Palpable lesions that are not measurable by radiologic or photographic evaluations may not be utilized as the only measurable lesion.
Must have measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) at baseline
Measurable disease (i.e., present with at least one measurable lesion per Response Evaluation Criteria in Solid Tumors [RECIST], version 1.1)
Measurable unresectable stage III or IV malignant melanoma and Response Criteria in Solid Tumors (RECIST), version 1.1
Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
Must have at least 1 measurable lesion assessable using standard techniques by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Phase I: Patients with advanced/metastatic solid tumors, with measurable or unmeasurable disease as determined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST version [v]1.1); baseline measurements must be obtained within 4 weeks prior to registration
Have evidence of measurable disease (according to Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1)
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1
Measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and Immune related Response Criteria (irRC).
PHASE I: Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria.
Measurable or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1), modified RECIST or Revised Response Criteria for Malignant Lymphoma
Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)
Participants must have at least one measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 that is amendable to biopsy.
Measurable metastatic disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 criteria
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1.
Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v.) 1.1 criteria.
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v.) 1.1 criteria
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)
Measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.
At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 criteria
Histologically and/or cytologically confirmed and radiographically measurable per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 colorectal cancer with liver metastasis. Patients may have other sites metastatic disease.
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Presence of measurable disease by computed tomography (CT) scan per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
At least one measurable tumor lesion as defined by Response Evaluation Criteria in Solid Tumors (Response Evaluation Criteria in Solid Tumors [RECIST]) version (v)1.1 criteria
Measurable disease as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST1.1)
Measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
For dose expansion phase, patients must have at least one site of measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (version 1.1)
Subjects must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1
Patients must have at least one measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v.)1.1, determined by investigator review
Subjects must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1.
Has measurable or evaluable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 for patients with solid malignancies and evaluable disease as assessed by bone scan and/or positron emission tomography (PET) scan
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 for patients with solid malignancies
Patients must have measurable disease according Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Participants must have measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 in the dose escalation portion of the trial. Participants in the expansion cohort must have measurable disease per RECIST version 1.1 or disease evaluable by assessment of tumor antigens.
Patients must have measurable/evaluable disease as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteria
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Measurable or evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1
At least one measurable disease lesion according to Response Evaluation Criteria In Solid Tumors (RECIST, version 1.1)
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (Version 1.1, 2009);
PHASE II SCLC: Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors, version (RECIST 1.1)
Presence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Have measurable disease as defined by Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.
Measurable disease as defined by immune related Response Criterion (irRC) or Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
At least two measurable lesions (including the index lesion) according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version (v)1.1
The patient must have radiographic measurable disease per Response Evaluation Criteria in Solid Tumor version 1.1 (RECIST 1.1) criterion
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
CAPMATINIB INCLUSION CRITERIA: Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Evaluable or measurable disease per Response Evaluation Criteria in Solid Tumors Version (RECIST)1.1
Subject must have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.
Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria
Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) (version [v]1.1)
Have at least one tumor lesion that can be accurately measured according to Response Evaluation Criteria in Solid Tumors (RECIST version [v]1.1)
Arms 1E, 2E, 3E: patients with at least one measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 that have not been previously irradiated
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Measurable or non-measurable (but evaluable) disease as defined via Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
Measurable disease, that is, presenting with at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST version 1.1).
Patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria
Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Additional Inclusion Criteria for Dose Finding Part and Dose Expansion Part:
Subjects who have measurable disease according to the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST version 1.1).
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1.
Patients must have histologically or cytologically confirmed stage IIIB or IV NSCLC with radiographic proof of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 for solid tumors
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 for solid tumors, within 28 days prior to registration
Participant must have measurable disease, as defined per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 per the Central Radiographic Assessment Committee (CRAC).
Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
At least one measureable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Have 2 or more measurable sites of disease as defined by either Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), or cutaneous lesions at least 1 cm in greatest dimension
Measurable disease per disease specific Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1-patients with bone as their only site of disease will not be eligible
Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1
All sites of disease must be evaluated within 4 weeks prior to randomization; patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Participants in the randomized portion of the study must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 criteria.
measurable and/or non-measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Disease must be measurable by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
For the dose-escalation phase, measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 (v1.1) is permitted; for the dose expansion phase, patients must have measurable disease by RECIST v1.1
Have measurable disease or nonmeasurable but evaluable disease as defined by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 or other tumor-specific criteria or disease assessable by physical exam or other methods if not measurable by RECIST
Measurable disease as determined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) criteria
Participants must have measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Has at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Subjects who have evaluable lesion per guideline of Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Dose Expansion Phase: at least one measureable lesion as defined by RECIST [Response Evaluation Criterion in Solid Tumors] version 1.1.
Measurable disease using clinically appropriate criteria for the type of malignancy, RECIST version 1.1 for solid tumors and Cheson 2007 for lymphoma
Evidence of measurable disease at screening as evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1)
Both measurable as well as non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 will be allowed
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria (for solid tumors) or equivalent criteria (for patients with non-solid tumor malignancies)
Measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) criteria Version 1.1.
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1
Measureable tumor by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1
Have measurable disease at the time of study enrollment as defined by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).
All sites of disease must be evaluated within 4 weeks prior to beginning therapy; patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1)
Measurable disease by response evaluation criteria in solid tumors (RECIST) version 1.1 (v1.1) prior to the administration of study treatment
Expansion Phase only: Has measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (Version 1.1, 2009), ie, has at least one measurable lesion
Subject has measurable or nonmeasurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Disease must be measurable with at least 1 uni dimensional measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
All sites of disease must be evaluated within 4 weeks prior to beginning therapy; patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Participant has radiographically-documented measurable disease, as per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1).
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Measurable disease at the time of study entry as defined by Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1).
The participant has metastatic disease or locally advanced disease that is measurable or nonmeasurable, but is evaluable disease by radiological imaging per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).
Subject has radiological documented measurable disease (ie, at least one measureable lesion as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1).
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1
At least one measureable lesion as defined by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.
Measurable or evaluable metastatic disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1 (v 1)
Have measurable disease based on Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST, v1.1)
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per response evaluation criteria in solid tumors version (RECIST) 1.1 criteria
Patients must have measurable disease (Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1])
Measurable or non-measurable disease is permitted as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) for phase 1b; for phase 2, patients must have measurable disease as defined in RECIST v1.1
At least 1 lesion on a computed tomography (CT) scan that is measurable as defined by Response Evaluation Criteria In Solid Tumors (RECIST), Version 1.1.
Measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 guidelines or evaluable disease; bone metastases must be evaluable
Patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
At least one measurable lesion and/or non-measurable disease evaluable according to Response Evaluation Criteria In Solid Tumors Version 1.1
At least one measurable lesion according to response evaluation criteria in solid tumours version 1.1
Presence of at least one site of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1
Patients must have measurable disease as per the revised Response Evaluation Criteria In Solid Tumors (RECIST) criteria (version 1.1)
Measurable (Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1]) indicator lesion not previously irradiated
Has measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 confirmed by CT or MRI scan within 28 days prior to enrollment.
Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v) 1.1 mRECIST or elevated AFP
All patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1
Part 2/Dose Expansion Only: Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1
Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
Subjects must have at least 1 measurable or evaluable tumor lesion according to RECIST 1.1 (Response Evaluation Criteria in Solid Tumors, version 1.1)
Measurable and/or evaluable disease as per the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1) [Groups 1, 2 of Part A and Group 3 of Part B] Inclusion Criteria Part A: MAD
Eligible study subjects must have histologic or cytologic confirmation of advanced, unresectable or metastatic solid tumors, and have at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines. All scans and x-rays used to document measurable disease must be done within 28 days before enrollment (ascites and bone lesions are not considered measureable disease).
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines. All scans and x-rays used to document measurable disease must be done within 28 days before enrollment (ascites and bone lesions are not considered measureable disease).
Participants must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria; baseline measurements and evaluation of ALL sites of disease must be obtained within 4 weeks prior to registration
Measurable disease defined as 1 or more target lesions according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1)
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines. At least one measurable lesion must be in the lungs.
Radiologically measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Measurable and/or evaluable disease based on Response Evaluation Criteria in Solid\n             Tumors (RECIST version 1.1)
Patients must have measurable disease, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Has measurable or evaluable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
For escalation: documentation by established staging studies or clinical examination to have measurable or non-measurable metastatic disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) on imaging studies CT
At least one measurable lesion according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1
Measurable disease in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Evaluable disease or disease measurable per modified Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
Patients must have measurable disease as defined by the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1); baseline measurements must be obtained within 4 weeks prior to initiating therapy; at least 1 of the tumor sites must be amenable to surgical or core biopsy
Measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
Patients may have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1 or non-measurable tumors
Metastatic disease documented on diagnostic imaging studies with measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1
Measurable disease according to Response Criteria for Solid Tumors (RECIST Version 1.1)
Participants must have measurable disease by response evaluation criteria in solid tumors (RECIST) version (v) 1.1 or bone-only disease with radiologic scans
Measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) (for phase II part only)
The participant has measurable or nonmeasurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 guidelines.
Patients must have computed tomography (CT) measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Participants must have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or disease evaluable by assessment of tumor antigens:
Measurable disease by CT or MRI per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) criteria
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Have measurable disease based on RECIST version (v) 1.1 for solid tumors
Must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 regardless of disease stage (e.g. localized, locally advanced, or metastatic)
At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
Has measurable disease based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by local radiology review.
Subject must have evaluable, progressive, and measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, Version 1.1